Indications
Chronic papillomavirus infection caused by oncogenic human papillomavirus, chronic recurrent herpes types 1 and 2, as part of the complex therapy of moderate (jaundice) form of acute hepatitis B.
$607.00
Active ingredient: | |
---|---|
Dosage form: | |
Indications for use: |
Chronic papillomavirus infection caused by oncogenic human papillomavirus, chronic recurrent herpes types 1 and 2, as part of the complex therapy of moderate (jaundice) form of acute hepatitis B.
The drug is administered subcutaneously.
The standard course of treatment for infections caused by oncogenic types of human papillomavirus includes injections of the drug at a dose of 1 mg every other day, for a total of 6 injections.
The standard course of treatment for recurrent herpes includes injections of the drug at a dose of 1 mg every other day, for a total of 3 injections per course.
In moderate forms of acute hepatitis B, the drug is administered after verification of the diagnosis at a dose of 1 mg 3 times a week for 3 weeks (a total of 9 injections).
To prepare the solution for injection, use 1 ml of 0.9% sodium chloride solution as a solvent.
Hypersensitivity, pregnancy and breast-feeding (stop for the duration of treatment), severe autoimmune diseases.
Children’s age.
Per 1 ampoule: Alloferon [Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine] 1.0 mg
Per 1 ampoule: Alloferon [Histidyl-glycyl-valyl-seryl-glycyl-histidyl-glycyl-glutaminyl-histidyl-glycyl-valyl-histidyl-glycine] 1,0 mg
Pharmacotherapy group: antiviral, immunomodulatory agent
ATX code J05AX, L03A
PHARMACOLOGICAL PROPERTIES
Pharmacodynamics
Alloferon is an oligopeptide. By the nature of its pharmacological action, it is most similar to interferon alpha. Alloferon is an effective inducer of endogenous interferon synthesis and an activator of the natural killer system. It can stimulate recognition and lysis of defective cells by cytotoxic lymphocytes. Experiments have demonstrated high efficacy against infections caused by influenza A and B viruses, hepatitis B and C, herpes types 1 and 2, and human papilloma. Alloferon does not have general toxicity, allergenic properties, mutagenic and carcinogenic effects, does not have an embryotoxic effect and does not affect the reproductive function.
Pharmacokinetics
It quickly penetrates into the blood, where it interacts with immunocompetent cells, after which it is difficult to determine the concentration of Alloferon due to the close structural similarity of its metabolites with serum proteins. An increase in the interferon concentration was observed 2 hours after use of the drug and remained at a high level (2-2.5 times higher than the usual background level) for 6-8 hours, reaching the initial values by the end of the day. Increased functional activity of natural killers was observed within 7 days after drug use.
Chronic papillomavirus infection caused by oncogenic human papillomavirus, chronic recurrent herpes types 1 and 2, as part of the complex therapy of moderate (jaundice) form of acute hepatitis B.
Hypersensitivity, pregnancy and breast-feeding (stop for the duration of treatment), severe autoimmune diseases.
Children’s age.
In some cases, weakness, dizziness, and the formation of new rash elements (with a herpetic infection) are possible.
In the treatment of chronic recurrent genital herpes, it can be prescribed in combination with acyclovir and its derivatives (the drugs have different mechanisms of action and complement each other in the treatment of viral infection). In acute hepatitis B, the drug is prescribed against the background of generally accepted basic therapy.
Interaction with other drugs was not detected.
The drug is administered subcutaneously. The standard course of treatment for infections caused by oncogenic types of human papillomavirus includes injections of the drug at a dose of 1 mg every other day, for a total of 6 injections. The standard course of treatment for recurrent herpes includes injections of the drug at a dose of 1 mg every other day, for a total of 3 injections per course. In moderate forms of acute hepatitis B, the drug is administered after verification of the diagnosis at a dose of 1 mg 3 times a week for 3 weeks (a total of 9 injections). To prepare the solution for injection, use 1 ml of 0.9% sodium chloride solution as a solvent.
To date, no cases of overdose of the drug have been established.
Lyophilized powder or porous mass of white color. Hygroscopic.
In monotherapy, Allokin-alpha is recommended for the treatment of papillomavirus infection caused by oncogenic types of the virus, in the absence of clinical and subclinical lesions of the cervix and anogenital region. As part of complex therapy – for the treatment of clinical and subclinical forms of lesions of the cervix and anogenital region with papillomavirus infection caused by oncogenic types of the virus. Treatment of chronic recurrent herpes types 1 and 2 is recommended to start at the very first signs of the disease. With hepatitis B – no later than the 7th day after the onset of jaundice.
Impact on the ability to drive a car and work with machineryIf you experience dizziness, you should refrain from driving and working with equipment.
Lyophilizate for the preparation of a solution for subcutaneous use of 1,0 mg. 1,0 mg in an ampoule of colorless glass. 1,2,3,5 or 10 ampoules are placed in a contour cell package. 1 or 2 contour cell packages together with the instructions for use are placed in a pack of cardboard
Store in a dark place at a temperature of 2 to 8 °C. Keep out of reach of children.
life is 2 years. Do not use after the expiration date.
Alloferon
By prescription
solution for injection
For adults as directed by your doctor
Genital Herpes, Cold Sores, Flu, Hepatitis
Reviews
There are no reviews yet